Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy comprising atorvastatin and an antihypertensive agent

An antihypertensive drug, atorvastatin technology, which can be used in drug combinations, medical formulations containing active ingredients, pharmaceutical formulations, etc., and can solve problems such as inability to normalize cardiovascular mortality

Inactive Publication Date: 2000-09-27
PFIZER INC
View PDF206 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, it has been demonstrated that attempts at hypertension intervention do not fully normalize cardiovascular mortality from coronary heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0096] The pharmaceutical composition of the present invention contains atorvastatin or a pharmaceutically acceptable salt thereof and an antihypertensive drug or a pharmaceutically acceptable salt thereof.

[0097] Atorvastatin can be prepared as described in US Patent 4,681,893, which is incorporated herein by reference. The hemicalcium salt of atorvastatin (currently known as Lipitor  marketed under the tradename ® ) can be prepared as described in US Patent No. 5,273,995, which is incorporated herein by reference.

[0098] The term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. The term "pharmaceutically acceptable cationic salt" is used to define (but is not limited to) alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as calcium and magnesium salts), aluminum salts, ammonium salts, and organic amines such as benzodiazepines. Raw (N,N'-di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical compound of atorvastatin or its pharmaceutically acceptable salt and an antihypertensive drug, a kit containing the compound and the use of the compound for treating patients with angina pectoris, atherosclerosis, mixed hypertension and hyperlipidemia Methods of treatment of individuals with cardiac disease and individuals with cardiac risk symptoms, including humans. The present invention also relates to a combination of atorvastatin or a pharmaceutically acceptable salt thereof and an antihypertensive agent with additive and synergistic effects, which can be used for treating angina pectoris, atherosclerosis, Individuals with mixed hypertension and hyperlipidemia and individuals with cardiac risk symptoms, including humans, are treated.

Description

[0001] The present invention relates to a pharmaceutical composition of atorvastatin (atorvastatin) or a pharmaceutically acceptable salt thereof and an antihypertensive drug, a kit containing the composition and the use of the composition for treating angina pectoris, atherosclerosis, mixed hypertension and Methods of treating hyperlipidemic individuals and individuals with cardiac risk symptoms, including humans. The present invention also relates to a compound with additive and synergistic effects of atorvastatin or a pharmaceutically acceptable salt thereof and an antihypertensive drug, so that the compound with additive and synergistic effects can be used for the treatment of patients with angina pectoris, atherosclerosis , individuals with mixed hypertension and hyperlipidemia and individuals with symptoms or signs of cardiac risk, including humans. Background of the invention [0002] The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/40A61K31/401A61K31/4025A61K31/404A61K31/41A61K31/4155A61K31/4245A61K31/44A61K31/4422A61K31/455A61K31/472A61K31/4965A61K31/517A61K31/55A61K31/554A61K31/675A61K38/00A61K45/06A61K45/08A61P3/06A61P9/10A61P9/12
CPCA61K45/06A61K31/40A61P11/06A61P3/00A61P3/06A61P9/00A61P9/10A61P9/12A61K2300/00
Inventor R·A·D·斯科特
Owner PFIZER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com